We have reported on a number of attempts to use tyrosine kinase inhibitors (TKIs) — alone or in combination with chemotherapy — in the treatment of men with castration-resistant prostate cancer (CRPC). Limited activity or efficacy has been reported to date. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: bicalutamide, castration-resistant, CRPC, metastatic, sorefanib, TKI, tyrosine kinase inhibitor | Leave a comment »
